Prevalence of multidrug-resistant organisms on palliative care patients in a university hospital-bound palliative care unit: A prospective cohort analysis.

ABSTRACT

BACKGROUND: Multidrug-resistant organisms are a growing challenge and burden to patient care. To date, there are only data concerning the prevalence of methicillin-resistant Staphylococcus aureus infections. Thus, numbers of other multidrug-resistant organisms can only be extrapolated and inferred from more or less comparable cohorts. AIM: To evaluate the prevalence of multidrug-resistant organisms on palliative care in-patients. DESIGN: A prospective cohort analysis. SETTING/PARTICIPANTS: A University Hospital-bound palliative care unit, in which all patients admitted to the unit were screened for inclusion. RESULTS: In total, 304 patients were included in this study. The prevalence for methicillin-resistant Staphylococcus aureus of 5.2% (95% confidence interval 2.9%-8.4%), for vancomycin-resistant Enterococcus faecium of 10.5% (95% confidence interval 7.2%-14.8%), for Ciprofloxacin-resistant-extended spectrum beta-lactamases isolates of 5.8% (95% confidence interval 3.4%-9.3%) and Ciprofloxacin-resistant Carbapenem-resistant Gram-negative bacteria of 0.3% (95% confidence interval 0%-1.3%) was calculated. Except for methicillin-resistant Staphylococcus aureus, patients carrying a multidrug-resistant organism had a significant longer duration of hospitalization. Median length of stay was 12 days (interquartile range 14.5, no multidrug-resistant organisms), 14.5 days (interquartile range 15, methicillin-resistant Staphylococcus aureus), 21 days (interquartile range 16.5, vancomycin-resistant enterococci), 22 days (interquartile range 20.75, Ciprofloxacin-resistant-extended spectrum beta-lactamases) and 32 days (interquartile range 22.00) for patients carrying two organisms. CONCLUSION: There is a high prevalence of all multidrug-resistant organisms within the hospitalized palliative care patients. However, the multidrug-resistant organisms do not seem to impact the survival within this cohort. Further studies should evaluate additional end-points, for example, quality of life, which are of special interest in this cohort.